Eisai launches Cogstate technology in Japan as digital brain performance tool
March 23, 2020
Eisai Co., Ltd (Tokyo) today announced the launch of “NouKNOW”, a digital tool for self-assessment of brain health based upon technology created by Cogstate. The Japanese product launch will occur on 31 March 2020 and will initially target municipalities providing health services to local residents and corporations providing health checks for employees. “NouKNOW” is conducted […]
Cogstate Expands Executive Team, Appointing Ken Billard as Chief Commercial Officer
November 19, 2019
New Haven, CT – November 19, 2019: The neuroscience technology company, Cogstate Ltd (ASX.CGS), announced today that Ken Billard has joined the company in the role of Chief Commercial Officer. Ken brings proven expertise in sales leadership and strategic partnering to Cogstate, where he will oversee the global sales organization to develop and execute strategies […]
Cogstate to Present at the NORD Rare Diseases and Orphan Products Breakthrough Summit
October 11, 2018
Presentation to Outline Innovative Methodology for Developing Indication-Specific Outcome Measures in Rare Disease Clinical Trials New Haven, CT – October 11, 2018: The cognitive science company, Cogstate Ltd (ASX.CGS) today announced a presentation entitled, “Methodology for Development of Indication-Specific Outcome Measures in Rare Disease Trials: An Innovative Research Approach” will be delivered at the National […]
Cogstate announces European approval for Healthcare offering
June 4, 2018
BOSTON – June 4, 2018: The cognitive science company, Cogstate, today announced that its Healthcare Division has received CE Mark approval for its Cognigram™ digital cognitive assessment system. “Cogstate Healthcare is excited about this significant regulatory milestone and we look forward to joining the fight against brain health challenges in European markets,” said Frank Cheng, […]
Cogstate Scientists Contribute to New Research Framework to Redefine Alzheimer’s Disease
April 17, 2018
A new research framework for understanding Alzheimer’s disease has been developed and released by the Alzheimer’s Association (AA) and the National Institute on Aging (NIA). This framework proposes an important shift in the definition of Alzheimer’s disease from being founded on the presence and nature of symptoms to one based on the identification and characterization of pathologic changes in the […]
Cogstate Establishes Rare Disease and Pediatric Center of Excellence
April 5, 2018
Dr. Pam Ventola appointed to lead implementation as Senior Science Director, Rare Disease and Pediatric Center of Excellence New Haven, CT – April 5, 2018: The cognitive science company, Cogstate Ltd (ASX.CGS) today announced the establishment of a Rare Disease and Pediatric Center of Excellence to lead all activities related to the selection and administration […]
Eric Siemers, M.D., Named Distinguished Medical Adviser at Cogstate
February 27, 2018
Siemers will provide expert advice for Cogstate in neurodegeneration research New Haven, CT – February 27, 2018: The cognitive science company, Cogstate Ltd (ASX.CGS) today announced the appointment of Eric Siemers, M.D., as Distinguished Medical Adviser. Dr. Siemers will provide expert advice for Cogstate’s pharmaceutical customers with regard to the design of clinical trials of […]
International publications validate Cogstate technology’s clinical value in detecting Postoperative Cognitive Dysfunction (POCD)
February 12, 2018
BOSTON – February 13, 2017: From the Interdisciplinary Conference on Orthopedic Value Based Care sponsored by the American College of Perioperative Medicine, Cogstate announced that the Cogstate Brief Battery™ has now been shown to be useful for guiding decision making about cognitive outcomes in older adults awaiting or undergoing surgery. Cogstate Brief Battery is the proprietary […]
Cogstate Strengthens Global Clinical Science Expertise with the Appointment of Senior Vice President, Dr. Chris Edgar
February 9, 2018
New Haven, CT – February 9, 2018: The cognitive science company, Cogstate Ltd (ASX.CGS) today announced the addition of Dr. Chris Edgar, Senior Vice President, Clinical Science to its global scientific leadership team. Dr. Edgar joins the Cogstate team in Europe as an experienced leader in cognitive assessment and clinical endpoint strategy. He will provide […]
Global Alzheimer’s Platform Foundation Selects Cogstate for Industry-First Rater Certification Program
January 24, 2018
Cogstate to Support Rater Training and Certification Program to Enable Accelerated Study Start-up in Alzheimer’s Disease Clinical Trials New Haven, CT – January 24, 2018: The cognitive science company, Cogstate Ltd (ASX.CGS) today announced it has been chosen by the Global Alzheimer’s Platform (GAP) Foundation to support GAP’s rater certification program (RCP) that will significantly […]
